Capromorelin Results Timeline: What Studies Measured, and When

Questions about a "capromorelin timeline" usually mean one thing: at what point did published studies actually take a measurement, and what did researchers find at that point? This page organises the verified literature by measurement timepoint, hours, days, weeks, months, and names the species studied in each case. It does not forecast outcomes for any person or animal. This page is for educational purposes only and is not medical advice; consult a licensed physician before making any health decisions.

What Capromorelin Is, in Context

Capromorelin is an orally active small-molecule agonist at the growth hormone secretagogue receptor (the ghrelin receptor). Pharmacologically, agonists at this receptor have been studied for two broad effect families: appetite and body-weight signalling, and growth hormone / IGF-1 release. Capromorelin is the active ingredient in FDA-approved veterinary products for appetite stimulation in dogs and cats; it is not an approved human therapeutic, and the bulk of the published timeline data comes from veterinary and laboratory-animal research rather than human trials.

One caution that runs through the whole class: not every vascular or gastrointestinal effect of a "ghrelin agonist" is mediated by the ghrelin receptor. Researchers analysing the related agent ulimorelin reported vascular actions that were independent of the ghrelin receptor (PMID 25687251), which is a reminder that class-level reasoning can mislead when applied to a specific molecule and a specific timepoint.

Timepoint 1: Hours After a Single Dose

Growth hormone and endocrine readouts

The earliest measurable signals in capromorelin work are hormonal. In healthy adult Beagle dogs, the study reported that capromorelin increased food consumption and body weight and raised growth hormone concentrations, while insulin-like growth factor 1 (IGF-1) concentrations were sustained with continued administration (PMID 27597271). The distinction matters for anyone reading a timeline: growth hormone is a pulsatile, short-window measurement taken around dosing, whereas IGF-1 is an integrative marker assessed across repeated days of dosing.

Metabolic readouts were also sampled on a short clock. Researchers examining glycemic control in healthy dogs measured glucose and insulin responses around capromorelin administration and reported transient changes rather than persistent alterations in glycemic status (PMID 35689953). Short-interval blood sampling is the only way such a signal becomes visible; a weekly weigh-in would never detect it.

Gastrointestinal motility in rodent models

Motility endpoints in rodents were measured in minutes to hours, not weeks. In rats with diet-induced constipation, the study reported that a centrally acting ghrelin receptor agonist acted as an effective colokinetic, with defecation endpoints assessed acutely after dosing (PMID 25616061). A companion line of work in spinal cord-injured rats reported stimulation of defecation by a centrally acting ghrelin receptor agonist, again on an acute post-dose timescale (PMID 21625243). Both are animal studies; neither establishes a human gastrointestinal timeline.

Timepoint 2: Days (Roughly 1-7)

Appetite and food intake in dogs

The most-cited short-horizon clinical dataset is a prospective, randomized, masked, placebo-controlled study in dogs with reduced appetite, in which the study administered capromorelin at 3 mg/kg once daily for 4 days and compared owner-assessed appetite and body weight against placebo (PMID 27859746). Researchers reported that a greater proportion of capromorelin-treated dogs showed improved appetite over that four-day window, and that body weight differed from placebo at the end of dosing (PMID 27859746). Four days is the measurement window that trial was designed to interrogate, it says nothing about what happens at week six.

Food intake in rabbits and birds

Several exotic- and laboratory-animal studies used multi-day food-intake logs. A comparison of capromorelin and mirtazapine in New Zealand White rabbits measured appetite and food consumption across a short dosing period (PMID 35981857). In budgerigars, researchers compared the effects of capromorelin, mirtazapine and cyproheptadine on food intake using daily intake measurements (PMID 40638135). In domestic pigeons, the study assessed both appetite and weight gain, pairing a short-interval intake measure with a slower body-weight measure (PMID 39772380). Avian and lagomorph physiology differs substantially from human physiology, and these results are reported here as species-specific findings, not as read-across.

Rodent body weight

In mice, researchers investigated whether enterally administered capromorelin affected body weight, tracking weight across the dosing period rather than relying on a single endpoint (PMID 39025662). Studies of this design illustrate a general point about timelines: body weight is a lagging indicator that requires repeated measurement before any trend can be distinguished from normal fluctuation (PMID 39025662).

Timepoint 3: Weeks

Weeks-scale data in the verified set comes mainly from feline work. A randomized, masked, placebo-controlled clinical trial in cats with unintended weight loss measured body weight at scheduled study visits and reported that capromorelin promoted weight gain relative to placebo over the trial period (PMID 41204815). The outcome chosen there, weight change in animals already losing weight, is different in kind from appetite scores in otherwise healthy animals, and the two should not be collapsed into a single "results" narrative.

Where dogs are concerned, the sustained IGF-1 signal reported in healthy Beagles sits between the days and weeks windows: the study described IGF-1 as sustained with continued dosing rather than as a one-off spike, which is a repeated-measures observation rather than a single timepoint (PMID 27597271).

Timepoint 4: Months, The Human Data

The one substantial human dataset in the verified set examined an oral growth hormone secretagogue in older adults. The study was a randomized, double-blind, placebo-controlled trial that assessed IGF-1, body composition and physical function over a year of daily oral dosing (PMID 19174493). Researchers reported increases in IGF-1 and in body weight and lean body mass at the 6-month assessment, with improvement in tandem-walk performance at that timepoint, and reported stair-climb performance improvement at 12 months (PMID 19174493). The trial had been planned to run longer than 12 months and was discontinued before completing its original schedule, which limits what can be said about outcomes beyond one year (PMID 19174493).

Two honest statements follow. First, human appetite and weight-gain endpoints of the kind measured in dogs and cats were not the primary design focus of that older-adult trial (PMID 19174493). Second, there is no verified human trial here measuring capromorelin for cachexia, body-composition change in younger adults, or gastrointestinal motility, those timelines exist only in animal work such as the rat colokinetic studies (PMID 25616061).

Measurement Timeline at a Glance

Why the Endpoint Chosen Determines the Apparent Timeline

A compound can look "fast" or "slow" depending entirely on what is being counted. Hormone concentrations change on a timescale of minutes to hours, which is why the Beagle study could report growth hormone effects around dosing (PMID 27597271). Food intake is counted per meal or per day, which is why a four-day dog trial could detect appetite differences (PMID 27859746). Body weight integrates intake, expenditure and fluid status, which is why the feline trial relied on scheduled weigh-ins across weeks (PMID 41204815). Functional performance measures, walking and stair-climbing, sit furthest out, which is why the older-adult trial reported them at 6 and 12 months (PMID 19174493).

Species is the second filter. Appetite-stimulant comparisons in rabbits and in budgerigars used different baseline diets, housing and intake-measurement methods than canine trials, and the authors framed their conclusions within those species (PMID 35981857, PMID 40638135). Results in pigeons were likewise reported as avian findings (PMID 39772380).

Adverse Events and Monitoring: What Studies Report

Short-horizon safety signals were monitored alongside efficacy endpoints in the controlled animal trials. The placebo-controlled canine appetite study collected adverse-event information over its four-day dosing period as part of a masked design (PMID 27859746), and the feline weight-loss trial was likewise randomized, masked and placebo-controlled, which allows observed events to be compared against a control group rather than attributed by impression (PMID 41204815). On the metabolic side, researchers specifically investigated glycemic control in healthy dogs and reported transient glucose and insulin changes, a finding that exists only because blood was sampled at short intervals (PMID 35689953).

For humans, tolerability information in the verified set is confined to the year-long older-adult trial, which was stopped before its originally planned duration, so long-term human safety characterisation is not established by that report alone (PMID 19174493). Full adverse-event tables are in the primary publications; readers wanting event-by-event detail should consult them directly rather than relying on summaries.

What the Literature Does Not Establish

• No human appetite-stimulation timeline. The controlled appetite and weight-gain trials in the verified set were conducted in dogs and cats (PMID 27859746, PMID 41204815).
• No human gastrointestinal motility data. The colokinetic and defecation findings came from rat models (PMID 25616061, PMID 21625243).
• No data beyond one year in humans. The older-adult trial reported outcomes at 6 and 12 months and did not complete its longer planned course (PMID 19174493).
• No assumption of receptor specificity for every effect. Work on a related agonist reported ghrelin receptor-independent vascular actions (PMID 25687251).

For background on pharmacology, approval status and the broader evidence base, see the overview at PeptideU's capromorelin learn page.

References

• A Prospective, Randomized, Masked, Placebo-Controlled Clinical Study of Capromorelin in Dogs with Reduced Appetite (Journal of Veterinary Internal Medicine, 2016)
• Capromorelin increases food consumption, body weight, growth hormone, and sustained insulin-like growth factor 1 concentrations when administered to healthy adult Beagle dogs (Journal of Veterinary Pharmacology and Therapeutics, 2017)
• Capromorelin promotes weight gain in cats with unintended weight loss: a randomized, masked, placebo-controlled clinical trial (Journal of Feline Medicine and Surgery, 2025)
• Effects of an oral growth hormone secretagogue in older adults (The Journal of Clinical Endocrinology and Metabolism, 2009)
• The effect of capromorelin on glycemic control in healthy dogs (Domestic Animal Endocrinology, 2022)
• Comparison of Effects of Capromorelin and Mirtazapine on Appetite in New Zealand White Rabbits (Oryctolagus cuniculus) (JAALAS, 2022)
• Effects of Capromorelin, Mirtazapine, and Cyproheptadine on Food Intake in Budgerigars (Melopsittacus undulatus) (Journal of Avian Medicine and Surgery, 2025)
• Effect of Capromorelin on Appetite and Weight Gain of Domestic Pigeons (Columba livia domestica) (Journal of Avian Medicine and Surgery, 2025)
• Investigating the Effect of Enterally Administered Capromorelin on Body Weight in Mice (Mus musculus) (Comparative Medicine, 2024)
• A ghrelin receptor agonist is an effective colokinetic in rats with diet-induced constipation (Neurogastroenterology and Motility, 2015)
• Stimulation of defecation in spinal cord-injured rats by a centrally acting ghrelin receptor agonist (Spinal Cord, 2011)
• Analysis of the ghrelin receptor-independent vascular actions of ulimorelin (European Journal of Pharmacology, 2015)